In laboratories at Washington State University, an old antiparasitic drug called niclosamide — long used to rid the body of tapeworms — has shown early signs of quieting the inflammatory processes that drive endometriosis in mice. For millions of women worldwide who live with a condition that medicine has never fully solved, this small discovery carries the particular weight of long-deferred hope. The path from mouse study to human treatment is neither short nor certain, but the possibility of repurposing a known, already-approved drug reframes a question that has lingered too long: not whethe
Tapeworm Drug Shows Promise Against Endometriosis in Early Research
Endometriosis causes debilitating symptoms affecting millions of women worldwide, with no current cure available.
An old drug finding new purpose in a disease that has resisted effective treatment
Mark
So niclosamide is a tapeworm drug. How does that connection even get made? It seems random.
Mimi
It's not random, actually. Researchers were looking at the inflammatory pathways that drive endometriosis, and niclosamide's mechanism—the way it disrupts cellular metabolism—turned out to interfere with those same pathways. Once you see that overlap, you test it.
Luke
But we're talking about mice here, right? The study showed it worked in mice. That's a meaningful first step, but it's not the same as showing it works in women.
Mimi
Absolutely not the same. But it's the necessary first step. You can't jump straight to human trials without animal evidence.
Mark
What makes this different from other endometriosis treatments that have been tried?
Mimi
Most current treatments are hormonal—they suppress the menstrual cycle or the hormones that drive it. Niclosamide works differently. It targets inflammation directly, which is a different angle on the disease.
Luke
And we don't know yet if that angle actually translates to human benefit. The mouse model might not capture everything about how endometriosis works in women.
Mark
How long until we know if this actually works for people?
Mimi
Clinical trials typically take years. You start small, establish safety, then move to larger groups to measure efficacy. We're probably looking at several years minimum.
Luke
And there's no guarantee it will work in humans the way it worked in mice. That's the honest version of the story.
Mark
But the fact that it's already an approved drug—that changes the timeline, doesn't it?
Mimi
It does. You don't have to prove basic safety from scratch. The regulatory path is shorter. If efficacy shows up in trials, getting it to patients could happen faster than with a brand-new compound.
Luke
Assuming efficacy shows up. Right now we have early evidence in an animal model. That's real, but it's not a treatment yet.
O Pulso
- Endometriosis has no cure, and the women it affects — millions globally — often spend years in pain before receiving even a diagnosis, let alone relief.
- Niclosamide, a decades-old tapeworm medication, has now disrupted that stagnation by demonstrating measurable reductions in endometriosis-like lesions in mouse models.
- The drug appears to interfere with the inflammatory pathways that allow misplaced uterine tissue to grow and bleed unchecked, pointing toward a biological mechanism worth pursuing.
- Because niclosamide is already approved and its safety profile is documented, the road to human trials could be faster and less costly than building a new drug from the ground up.
- Clinical trials in human subjects are the essential next step — researchers must confirm the right dose, monitor side effects, and measure real reductions in pain and lesion burden.
- The timeline is years, not months, but the field has shifted from resignation to possibility, and for a condition this long neglected, that shift is itself significant.
In laboratories at Washington State University, an old antiparasitic drug called niclosamide — long used to rid the body of tapeworms — has shown early signs of quieting the inflammatory processes that drive endometriosis in mice. For millions of women worldwide who live with a condition that medicine has never fully solved, this small discovery carries the particular weight of long-deferred hope. The path from mouse study to human treatment is neither short nor certain, but the possibility of repurposing a known, already-approved drug reframes a question that has lingered too long: not whether a better answer exists, but how soon it might arrive.
Researchers at Washington State University have discovered that niclosamide — a drug developed decades ago to treat tapeworm infections — appears to reduce the signs of endometriosis in mice. For a condition that affects millions of women worldwide and has no cure, even early-stage findings carry unusual weight.
Endometriosis occurs when tissue resembling the uterine lining grows outside the uterus, most often in the pelvis. During menstruation, this misplaced tissue bleeds as the uterine lining does, but the blood cannot escape. The result is inflammation, scarring, and pain severe enough to disrupt work, relationships, and daily life. Current options — surgery and hormonal contraceptives — manage symptoms without addressing the underlying disease, and neither works for everyone.
Niclosamide has been in use since the mid-20th century, originally designed to disrupt a parasite's metabolism. When WSU researchers applied it to mice with endometriosis-like lesions, they observed a reduction in severity. The drug appears to interfere with the inflammatory pathways that drive the condition's progression — a mechanism that, if confirmed in humans, could represent a meaningful new approach.
The appeal of repurposing an existing drug is practical as well as scientific. Niclosamide's safety profile is already documented, its side effects are known, and the infrastructure for manufacturing and distribution exists. If human trials confirm its effectiveness, the path to availability could be considerably shorter than developing an entirely new compound — and for patients who have cycled through inadequate treatments for years, speed is not a minor consideration.
What comes next is the harder work: clinical trials to establish correct dosing, monitor side effects in an endometriosis population, and measure whether the drug genuinely reduces pain and lesion burden in living patients. That process will take years. But the conversation has shifted — from the limits of what medicine currently offers to the possibility of what an old drug, given new purpose, might yet provide.
Researchers at Washington State University have found that niclosamide, a drug developed decades ago to kill tapeworms, appears to reduce the hallmarks of endometriosis in mice. The discovery, reported across multiple outlets, suggests that an old pharmaceutical sitting on pharmacy shelves might offer relief to millions of women living with a condition that currently has no cure.
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, typically in the pelvis. The misplaced tissue bleeds during menstruation just as the uterine lining does, but the blood has nowhere to go. It accumulates, causing inflammation, scarring, and pain that can be severe enough to interfere with work, relationships, and daily life. The condition affects an estimated millions of women worldwide, yet treatment options remain limited. Surgery can remove visible lesions, and hormonal contraceptives can suppress symptoms, but neither addresses the underlying disease, and neither works for everyone.
Niclosamide has been used since the mid-20th century as an antiparasitic agent, primarily to treat tapeworm infections. It works by disrupting the parasite's metabolism. When WSU researchers tested the drug in mice with endometriosis-like lesions, they observed a reduction in the signs and severity of the condition. The mechanism appears to involve the drug's ability to interfere with inflammatory pathways that drive endometriosis progression. This finding opens a door that pharmaceutical development rarely gets to walk through: the possibility of repurposing an existing, already-approved medication rather than starting from scratch with a new compound.
The appeal of drug repurposing is substantial. Niclosamide has a known safety profile in humans. Its side effects are documented. Manufacturing and distribution infrastructure already exist. If the drug proves effective in human trials, the path to making it available could be faster and cheaper than developing an entirely new treatment. For women with endometriosis, speed matters. Many spend years seeking a diagnosis, cycling through treatments that don't work, and managing pain that conventional medicine has not yet solved.
Local patients in the WSU research community have spoken publicly about the toll endometriosis takes. Their accounts underscore why even early-stage research generates hope. The condition is not merely uncomfortable; for many, it is disabling. Work absences, canceled plans, and the emotional weight of chronic pain without adequate treatment create a burden that extends far beyond the physical symptoms.
What happens next is the critical phase. Mouse studies, while promising, do not guarantee human efficacy. Niclosamide must now move into clinical trials with human subjects. Researchers will need to establish the correct dose, monitor for side effects in an endometriosis population, and measure whether the drug actually reduces pain and lesion burden in living patients. The timeline for such trials is measured in years, not months. But for a condition that has resisted effective treatment for so long, the prospect of an old drug finding new purpose is enough to shift the conversation from what cannot be done to what might be possible.
Citações Notáveis
Local patients in the WSU research community have spoken publicly about the toll endometriosis takes, describing it as disabling rather than merely uncomfortable— Endometriosis patients in the WSU research area
Quer a matéria completa?
Leia o original em Google News ↗
Health & Medicine